RxDoctor Payments DataLook up a doctor →

David Dryland, MD

Rheumatology · Ashland, ORNPI 1205896115

Payments from drug & device makers

$3,050in general payments, 2019–2025

Across 149 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$538
  • Amgen$409
  • AbbVie$376
  • AstraZeneca$315
  • Johnson & Johnson$297
  • Novartis$244
  • plus $872 from 18 others

What the payments were for

  • Food & beverage$3,037100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,050 in reported general payments places this provider in the 70th percentile of 79 rheumatology providers in Oregon.

See all rheumatology providers in Oregon

Medicare billing

Part B allowed, 2024
$2,920,103
Medicare patients
622
Services billed
215,371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept255$2,105,403
Humira(Cf) PenAdalimumab89$779,265
EnbrelEtanercept36$339,495
Orencia ClickjectAbatacept40$262,610
StelaraUstekinumab12$215,771
BenlystaBelimumab28$142,836
Humira(Cf)Adalimumab19$125,355
Cosentyx Sensoready (2 Pens)Secukinumab16$114,805
Cimzia (2 Pack)Certolizumab Pegol15$88,668
Humira PenAdalimumab13$87,969
Hydroxychloroquine Sulfate699$37,178
Leucovorin Calcium334$36,624
MethotrexateMethotrexate Sodium857$26,525
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen610$16,221
Prednisone896$10,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$409$339,49536 claims
Johnson & JohnsonStelara$297$215,77112 claims
GSKBenlysta$180$142,83628 claims
AbbVieHumira(Cf)$376$125,35519 claims
UCB, Inc.Cimzia (2 Pack)$538$88,66815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 rheumatology providers in Oregon.

Other rheumatology in Ashland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →